Glucotrack has a reported 9.99% beneficial stake associated with White Lion Capital LLC, representing 79,734 common shares. The position includes 77,492 shares already owned, while potential acquisitions through warrants, a note and agreements remain subject to stated ownership limits and a passive-investment certification.
Key Highlights
- White Lion directly owns 77,492 Glucotrack common shares.
- Beneficial ownership was calculated using 798,144 Glucotrack shares outstanding as of Aug. 28, 2026.
- White Lion certified that the position was not held to change or influence Glucotrack’s control.
Glucotrack, Inc. (NASDAQ: GCTK) has a reported 9.99% beneficial stake associated with White Lion Capital LLC, representing 79,734 common shares. The position covers securities held directly and potential share acquisitions under several agreements and instruments.
White Lion’s Position Includes 77,492 Owned Shares
White Lion owns 77,492 Glucotrack shares, while the reported beneficial ownership also reflects possible acquisitions connected with a common stock purchase agreement, commitment shares held in abeyance, common warrants, a securities purchase agreement, a senior convertible Promissory Note and SPA warrants. The stock purchase agreement took effect July 14, 2026, and Glucotrack may require White Lion to purchase shares under its terms. Common warrants and SPA warrants are subject to a 4.99% ownership ceiling, with each limit eligible to rise to 9.99% after sixty-one days’ written notice. The note carries a 4.9% ceiling that can increase to 9.9% through written notice. White Lion said it currently has no right to acquire shares held in abeyance or shares through the common warrants and note because of these limits.
Passive Ownership Certification Sets Boundaries
The beneficial ownership calculation uses 798,144 Glucotrack common shares outstanding as of Aug. 28, 2026. White Lion’s Schedule 13G was made under Rule 13d-1(c), and Yash Thukral signed the certification as managing partner. White Lion certified that the securities were not acquired or held to change or influence Glucotrack’s control. The report also states that the 9.99% calculation applies for Rule 13d-3 purposes even if White Lion later ceases to hold its currently owned shares.



Please wait processing your request...